Self-assembling complex for targeting chemical agents to cells
The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.
1. A method of treating a disease in an individual, comprising:
administering a therapeutically effective amount of a drug delivery molecule to the individual, the drug delivery molecule comprising:
a polypeptide sequence adapted to target and penetrate a type of cell,
a nucleic acid sequence bound to the polypeptide sequence via electrostatic interactions, and
a chemical agent non-covalently linked to the nucleic acid sequence.
2. The method of claim 1 , wherein the disease is breast cancer.
3. The method of claim 1 , wherein the chemical agent is a chemotherapeutic agent.
4. The method of claim 1 , wherein the chemical agent is doxorubicin.
5. The method of claim 1 , wherein the polypeptide sequence comprises a targeting ligand, an endosomolytic domain, or a polylysine motif.
6. The method of claim 1 , wherein the individual is a human.
7. The method of claim 1 , wherein the type of cell is a glioma cell.
8. The method of claim 1 , wherein the polypeptide sequence comprises PBK10.
9. The method of claim 1 , wherein the disease is metastatic cancer.
10. The method of claim 1 , wherein the disease is cancer.
11. The method of claim 1 , wherein the type of cell is a breast cancer cell.
12. The method of claim 1 , wherein the type of cell is a HER2+ breast cancer cell.
13. The method of claim 1 , wherein the polypeptide sequence comprises a targeting ligand.
14. The method of claim 13 , wherein the targeting ligand comprises Her.
15. The method of claim 1 , wherein the polypeptide sequence comprises a penton base or a variant thereof.
16. The method of claim 15 , wherein the penton base comprises an EGD motif in place of an RGD motif.
17. The method of claim 15 , wherein the polypeptide sequence further comprises a targeting ligand.
18. The method of claim 17 , wherein the targeting ligand comprises Her.
19. The method of claim 1 , wherein the polypeptide sequence comprises a polylysine motif.
20. The method of claim 19 , wherein the polypeptide sequence further comprises a penton base or a variant thereof.
21. The method of claim 20 , wherein the polypeptide sequence further comprises a targeting ligand.
22. The method of claim 21 , wherein the targeting ligand comprises Her.
23. The method of claim 1 , wherein the nucleic acid sequence comprises a sequence according to SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
24. The method of claim 1 , wherein the nucleic acid sequence is a double stranded nucleic acid sequence comprising a first nucleic acid molecule having a sequence according to SEQ ID NO: 6, and a second nucleic acid molecule having a sequence according to SEQ ID NO: 7.
25. The method of claim 1 , wherein the chemical agent intercalates with the nucleic acid sequence.
26. The method of claim 1 , wherein the polypeptide sequence comprises a targeting ligand, a penton base or a variant thereof, and a polylysine motif.
27. The method of claim 1 , wherein the polypeptide sequence comprises HerPBK10.
28. The method of claim 27 , wherein the nucleic acid sequence is a double-stranded nucleic acid sequence.
29. The method of claim 28 , wherein the chemical agent comprises doxorubicin.
30. The method of claim 29 , wherein the doxorubicin intercalates with the double stranded nucleic acid sequence.
31. The method of claim 28 , wherein the double-stranded nucleic acid sequence comprises a first nucleic acid molecule having a sequence according to SEQ ID NO: 6, and a second nucleic acid molecule having a sequence according to SEQ ID NO: 7.
32. The method of claim 31 , wherein the chemical agent comprises doxorubicin.
33. The method of claim 32 , wherein the doxorubicin intercalates with the double stranded nucleic acid sequence.